Guardant Health (GH) news
Recent news
Guardant Health's test cleared for AstraZeneca's ETCAMAH
The U.S. Food and Drug Administration (FDA) has approved Guardant Health’s Guardant360 CDx as a companion diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with an ESR1 mutation . This marks a…
AInvest Wire · 6d agoGuardant Health's Guardant360 CDX gets EU CDX approval
Guardant Health has received IVDR certification for Guardant360 CDx liquid biopsy test across solid tumors in the European Union, marking a significant regulatory milestone for the company. This certification enables the test to be used as a companion diagnostic for identifying genetic alterations…
AInvest Wire · 6d agoGuardant Health (GH) fell 5.17% in intraday trading after rising 5.3% on Monday, marking a reversal of the prior session's move.
Guardant Health (NASDAQ: GH) experienced a 5.17% decline in intraday trading on Friday, following a 5.3% increase on Monday. This movement marked a reversal from the prior session’s performance. The stock’s fluctuation highlights the volatility often seen in the biotechnology sector, particularly…
AInvest Wire · Oct 6, 2026Guardant Health (GH) gained 5.23% in intraday trading after rising 6.65% on Monday, marking a continuation of the prior session's move.
Guardant Health (GH) gained 5.23% in intraday trading on Tuesday, following a 6.65% increase on Monday, reflecting a continuation of the upward momentum seen in the prior session. The stock has shown strong performance across multiple timeframes, with a year-to-date return of 73.11% , significantly…
AInvest Wire · Sep 15, 2026Guardant Health, - Evicore by Evernorth to cover shield blood test for CRC screening effective Jan 1, 2027
Guardant Health, Inc. (Nasdaq: GH) announced that its Shield™ blood test for colorectal cancer (CRC) screening will be covered by Evicore, a subsidiary of Evernorth Health Platform, effective January 1, 2027. This coverage expansion adds to the existing support from Carelon Healthcare Services and…
AInvest Wire · Sep 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.